Form 4: Seres Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Marella Thorell, EVP and Chief Financial Officer of Seres Therapeutics, acquires stock options for 650,000 shares.
Summary
- Marella Thorell, the EVP and Chief Financial Officer of Seres Therapeutics, acquired stock options on February 7, 2025.
- The options grant the right to buy 650,000 shares of common stock at an exercise price of $0.782 per share.
- The options vest as to 25% of the shares on February 7, 2026, with the remaining shares vesting in 12 equal quarterly installments thereafter.
- The options expire on February 6, 2035.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting the grant of stock options. The sentiment is slightly positive as it indicates executive alignment with company performance.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of stock option acquisition |
| 02/07/2026 | First vesting date for 25% of the shares |
| 02/06/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.